CI vs HUM
Cigna Group and Humana Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | CI | HUM |
|---|---|---|
| Revenue | $274.9B | $129.7B |
| Net income | $6.0B | $1.2B |
| Gross margin | 21.8% | — |
| Net margin | 2.3% | 0.9% |
| Return on equity | 14.4% | 7.0% |
| Diluted EPS | $22.18 | $9.84 |
| Dividend / share | $6.04 | $3.54 |
| Payout ratio | 27.0% | 36.2% |
| Free cash flow | — | $375.0M |
| Equity | $41.7B | $17.7B |
| Net debt / equity | 0.57× | 0.46× |
| Current ratio | 0.85× | 2.00× |
| Revenue CAGR 5y | 11.4% | 10.9% |
| Profit CAGR 5y | — | −18.8% |
CI bills 2.1× the revenue of HUM, and keeps more of each dollar of revenue as profit (2.3% against 0.9%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Revenue by year
10 years side by side
| Fiscal year | CI | HUM |
|---|---|---|
| FY2025 | $274.9B | $129.7B |
| FY2024 | $247.1B | $117.8B |
| FY2023 | $195.3B | $106.4B |
| FY2022 | $180.5B | $92.9B |
| FY2021 | $174.1B | $83.1B |
| FY2020 | $160.4B | $77.2B |
| FY2019 | $153.6B | $64.9B |
| FY2018 | $48.6B | $56.9B |
| FY2017 | $41.8B | $53.8B |
| FY2016 | $39.8B | $54.4B |
Net income by year
Bottom line
| Fiscal year | CI | HUM |
|---|---|---|
| FY2025 | $6.0B | $1.2B |
| FY2024 | $3.4B | $1.2B |
| FY2023 | $5.2B | $2.5B |
| FY2022 | $6.8B | $2.8B |
| FY2021 | $5.4B | $2.9B |
| FY2020 | $8.5B | $3.4B |
| FY2019 | $5.1B | $2.7B |
| FY2018 | $2.6B | $1.7B |
| FY2017 | $2.2B | $2.4B |
| FY2016 | $1.8B | $614.0M |